1. PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis
- Author
-
Peng Shen, Qi Jiang, Feifei Yan, and Mengye He
- Subjects
Oncology ,Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,Advanced breast ,medicine.medical_treatment ,Cancer ,General Medicine ,medicine.disease ,law.invention ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Breast cancer ,Randomized controlled trial ,law ,030220 oncology & carcinogenesis ,Meta-analysis ,Internal medicine ,PARP inhibitor ,medicine ,030212 general & internal medicine ,business - Abstract
Background: We conducted this meta-analysis to compare the efficacy and safety of PARP inhibitors with or without chemotherapy versus chemotherapy alone for advanced breast cancer. Methods: A meta-analysis and trial sequential analysis were performed using RevMan 5.2 analysis software. Results: Six eligible randomized clinical trials involving 2080 patients were included. Regimens containing PARP inhibitors were significantly associated with higher objective response rate, longer progression-free survival and overall survival. The PARP inhibitor regimen group had a significantly higher rate of grade ≥3 thrombocytopenia than the chemotherapy-only group. Conclusion: Regimens containing PARP inhibitors are effective and safe for BRCA-mutated advanced breast cancer patients. The efficacy appears to be only marginal in patients with BRCA status unselected.
- Published
- 2021
- Full Text
- View/download PDF